8-K: Grace Therapeutics Secures $30 Million in Private Placement to Advance GTx-104

Grace Therapeutics announces a private placement aiming to raise up to $30 million to support the development of GTx-104.

Summary

• Grace Therapeutics has entered into securities purchase agreements to raise up to $30 million through a private placement.
• The financing includes an initial $15 million and potential additional $15 million upon warrant exercise.
• The private placement is led by Nantahala Capital and ADAR1 Partners, LP, with participation from other healthcare-focused institutional investors.
• The company will issue 4,418,292 shares of common stock (or pre-funded warrants) and accompanying warrants to purchase the same number of shares.
• The combined purchase price is $3.395 per share and accompanying warrant.
• Each warrant is exercisable for one share at $3.395, immediately exercisable, and expires on the earlier of 60 days after FDA approval of GTx-104's NDA or September 25, 2028.
• The company intends to use the net proceeds for general corporate purposes and pre-commercial development of GTx-104.
• The financing is expected to close on February 11, 2025, pending customary closing conditions.
• A registration statement will be filed with the SEC to register the resale of the shares and underlying warrant shares.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results and a successful capital raise, indicating a favorable outlook for the company. However, the inherent risks associated with drug development and regulatory approval temper the overall sentiment.

Positives

• The Phase 3 STRIVE-ON Safety trial met its primary endpoint and provided evidence of clinical benefit over orally administered nimodipine.
• The financing provides capital to advance the pre-commercial development of GTx-104.
• The company intends to submit its NDA in the first half of 2025.
• The financing is led by reputable healthcare-focused institutional investors.

Negatives

• The financing involves the issuance of a significant number of shares, which could dilute existing shareholders.
• The company is dependent on the successful development and regulatory approval of GTx-104.
• The company may not receive the full $30 million if the warrants are not exercised.

Risks

• The company may not receive the full $15 million from warrant exercises.
• The development and regulatory approval of GTx-104 may face delays or setbacks.
• The company may encounter challenges in the commercialization of GTx-104.
• The company's financial performance is dependent on the success of GTx-104.

Future Outlook

Grace Therapeutics intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund pre-commercial development of GTx-104, a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The company intends to submit its NDA in the first half of 2025.

Management Comments

• 'We are thrilled that the STRIVE-ON trial results have exceeded our expectations and demonstrated improvements in clinical outcomes of these patients,' said Prashant Kohli, CEO of Grace Therapeutics.
• 'Importantly, the data provide both medical and pharmacoeconomic evidence of the potential benefit of GTx-104 in aSAH patients.'

Industry Context

The announcement highlights the ongoing efforts to improve treatment options for aSAH, a rare and life-threatening condition. The current standard of care, oral nimodipine, has limitations, and GTx-104 aims to address these challenges with a novel intravenous formulation.

Comparison to Industry Standards

• The current standard of care for aSAH is oral nimodipine, which has been used for nearly 40 years.
• NYMALIZE (oral liquid) tempers the risk of error, but has tolerability challenges (e.g., severe diarrhea) due to solubility limitations of nimodipine.
• Nimodipine is administered six times per day for up to 21 days.
• GTx-104 aims to address the limitations of oral nimodipine, such as high pharmacokinetic variability, inconsistent plasma concentration, and administration challenges.
• GTx-104 has been administered in over 150 healthy volunteers and was well tolerated with significantly lower interand intra-subject pharmacokinetic variability compared to oral nimodipine.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares, but also potential for increased value if GTx-104 is successfully developed and commercialized.
• Patients: Potential for a new and improved treatment option for aSAH.
• Investors: Opportunity to invest in a late-stage biopharma company with a promising drug candidate.

Next Steps

• The company intends to submit its NDA in the first half of 2025.
• The company will file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock purchased in the private placement and shares of common stock underlying the warrants.

Key Dates

Keywords

GTx-104, private placement, financing, securities purchase agreement, warrants, NDA, aneurysmal Subarachnoid Hemorrhage, aSAH, Nantahala Capital, ADAR1 Partners, Grace Therapeutics